openPR Logo
Press release

Companion diagnostics Market: Companion diagnostic are used to determine patient personal molecular profile, 2016 - 2022

11-22-2016 03:00 PM CET | Health & Medicine

Press release from: Persistence Market Research Pvt. Ltd

Companion diagnostics Market, Companion diagnostics, Companion diagnostic Market

Companion diagnostics Market, Companion diagnostics, Companion diagnostic Market

The few companion diagnostics are already available in the market for specific types of cancer and many are already under clinical development. Companion diagnostics test depends on finding a specific biomarker in the patient and hence biomarker presence or absence determines whether or not the patient will respond to the treatment. This test require a biopsied tissue to access the expression of biomarker protein or mutant or aberrant genes. Companion diagnostics are also used in drug development process by determining Companion biomarker that help predict likely response of toxicity. There are different types of biomarker available in market for few of the disease as follows:

• Colorectal Cancer
• Lung Cancer
• Breast Cancer
• Gastric Cancer
• Melanoma Cancer
• Genital Cancer
• Other (Infectious disease, HIV)

Companion diagnostics market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs. Awareness among physician and patient about the drug toxicity is helping the market to dive further however in developing countries due to less awareness it is not as much in practice as in developed countries but the developing countries with huge population like India & china have a huge potential to pool in the market share. Lack of skilled professionals in the developing countries and lack of awareness is hampering the growth of companion diagnostics in developing countries. Other challenges in the development of companion diagnostics is the logistic issues raised so as to develop companion diagnostics and drug together.

Request for TOC @

Companion diagnostic can be segmented on the basis of its use in indications.

• Cardiovascular
• Central Nervous System
• Oncology
• Inflammation
• Virology

Oncology being the highest revenue generating segment and most of the companion diagnostic have been developed to detect one or the other cancer biomarkers.

Companion diagnostics has developed its space in drug discovery and diagnostics by identifying the biomarkers. Companion Diagnostic test includes biomarker test which helps in making a better decision making in therapy use. The goal of diagnostic drug is specially linked to therapeutic drug and increasing its safety and efficacy. However it is difficult to find the predictive biomarker in the early stage of development of drugs, can only be established after a significant number of patients much beyond the usual number in Phase III trials.

Request for Sample Report @

Some of the key market players in companion diagnostic market are Qiagen, Abbott, Genomic Health, Roche Holdings, Life Technologies, Thermo Fischer Scientific, Myriad Genetics, Agilent Technologies, Amgen, Sysmex, Myriad Genetics, Protagen Diagnostics to name a few.

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Companion diagnostics Market: Companion diagnostic are used to determine patient personal molecular profile, 2016 - 2022 here

News-ID: 385771 • Views: 417

More Releases from Persistence Market Research Pvt. Ltd

Transformer Oil Market to hit US$ 8.7 Bn by 2032, says Persistence Market Resear …
Transformer Oil Market The global market for transformer oil is estimated at US$ 4 Bn in 2022. Transformer oil demand is anticipated to increase at 8% CAGR through 2032. By 2032, the market is anticipated to reach a value of US$ 8.7 Bn, Transformers and switchgear are the key application areas of transformer oil, accounting for 88% of overall consumption. Top countries driving the global transformer oil market are China, India, and the
Biodiesel Market Worth US$ 59 Bn by 2032 - Exclusive Report by Persistence Marke …
Biodiesel Market The global biodiesel market was valued at US$ 40 Bn in 2021. The market for biodiesel is projected to increase at 3.6% CAGR between 2022 and 2032. According to Persistence Market Research, global biodiesel consumption is expected to reach US$ 59 Bn by the end of 2032. Europe, East Asia, and South Asia & Pacific are expected to remain key regional markets in the biodiesel business. Request For Free Sample Report@ Biodiesel is a
Soil Fertility Testing Market Size to Surpass US$ 2.28 billion by 2033 | Persist …
Soil Fertility Testing Market Soil fertility testing market has been estimated to be valued at US$ 1,164.9 million in 2022. Market size for soil fertility testing is projected to reach US$ 2,282.5 million by the end of 2033, is projected to grow with CAGR of magnitude 6.3%. Click Here to Get Free Sample Copy of this Report@ The Soil Fertility Testing Market is a rapidly growing sector of the agricultural industry, as farmers and growers
Gas Pressure Regulator Market is expected to reach US$ 2.4 Bn in the year 2023
Gas Pressure Regulator Market The gas pressure regulator market is expected to reach US$ 2.4 Bn in the year 2023, thereby placing itself as the "high value" market. As a result, utilization of gas pressure regulators in diverse industries is expected to surge. According to a research report released by Persistence Market Insights, the gas pressure regulators market is expected to witness 4% CAGR during the forecast period (2019-2029). Click Here to Get

All 5 Releases

More Releases for Companion

Companion Animal Drugs - Key Market Statistics
Companion animals are pets kept primarily for company, entertainment, and safety. Owners of companion animals consider them to be family, friends, and confidants. Dogs, cats, birds, rabbits, horses, goats, gerbils, rats, mice, and amphibians, others are considered as companion animals. Read Report Overview - According to the American Society for the Prevention of Cruelty to Animals (ASPCA) defines companion animal to be domesticated or domestically-bred whose emotional, physical, social, and behavioral
Companion Animal Vaccine – Improving The Health Of Companion Animals In A Cost …
The companion animal vaccines market is expected to witness significant growth during the forecast period due to launch of vaccines for companion animals. For instance, in December 2017, Zoetis Inc. announced the launch of Vanguard CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against the two strains of the virus known to be circulating in the U.S. Moreover, the
Companion Diagnostics Market - Easing of Regulatory Policies to Drive Global Dem …
Companion diagnostics include two types of tests namely tests which are developed along with target drugs and the other developed after the commercialization of drugs. Companion diagnostics combined with targeted therapeutics are being seen as a major breakthrough in the personalized medicine field. Companies operating in the companion diagnostics market are seeking an effective growth strategy in the development of this concept drug-diagnostic interaction as the healthcare sector is shifting
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.
Companion Diagnostics Market - Easing of Regulatory Policies to Drive Global Dem …
Due to the dominance of the top three players in the global companion diagnostics market, the nature of the market is highly oligopolistic, says Transparency Market Research in a new study. The leading companies operating in the market are focusing on protecting their patent rights to retain exclusivity. The top three companies in the companion diagnostics market are Roche Holdings followed by Qiagen N.V., and Agilent Technologies. Together they comprise